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Abstract  
BACKGROUND: Colon cancer is one of the most common malignancies worldwide. Colonic 
adenoma and ulcerative colitis (UC) are important precancerous lesions. Vascular Endothelial 
Growth Factor (VEGF) is a well-known pro-angiogenic factor plays important role in physiologic and 
pathologic conditions and in neovascularization in cancer and hence becomes a potential target for 
anti-angiogenic cancer therapy.  
AIM: This study investigated VEGF immunohistochemical expression in colon cancer and its 
precancerous lesions.  
MATERIAL AND METHODS:  Paraffin blocks from two hospitals were collected in a year: Colon 
cancer: 20 cases, colonic adenoma: 15 cases, UC: 15 cases and 5 controls from normal mucosa. 
VEGF was assessed immunohistochemically using a primary anti-VEGF antibody (VG1, Dako, 
Denemark).  
RESULTS: Median age was 49 years (range 31-52) in cancer, 40 years (range 31-52) in adenomas 
and 33 years (range 27-43) in UC. VEGF expression was negative in control, significantly strongly 
positive in 90% of colonic adenocarcinoma (p= 0.001), significantly positive in adenomas (p= 0.002) 
- the weak positivity significantly seen in mild dysplasia (p= 0.001) - and significantly positive in 
73.3% of UC cases (p=0.022).  
CONCLUSION: The significant increase in positivity of VEGF in precancerous to cancerous lesions 
may point to its potential role in the pathogenesis and progression of colonic neoplasia. 
 
 
 
 
 
Introduction 
Colon cancer is one of the most common 
malignancies in Egypt with about 142 registered 
cases per year in one Government (the only available 
population based registry) [1] and the third leading 
cause of cancer-related mortality according to the 
latest Egyptian registry [2].  
The gradual increase of incidence and 
mortality of colon cancer recommended a deeper 
understanding of its pathogenesis and biology which 
is crucial for establishing novel therapeutic and 
diagnostic strategies [3].  
A number of colon carcinoma risk factors 
have been identified including; life style, obesity, diet 
and smoking.  It    may also evolve from a number of 
precancerous lesions, among which adenoma and 
ulcerative colitis (UC) are recorded. 
The adenoma –carcinoma progression in 
colon is a multistep process characterized by genetic 
alterations and mutation accumulation [5, 6]. Based 
on epidemiological, clinical, postmortem, and 
molecular biological studies, the concept that 
colorectal cancers (CRC) may arise from pre-existing 
adenomas is now widely accepted [7, 8]. 
Ulcerative colitis (UC) is a chronic and 
relapsing inflammation of the colonic mucosa; the 
continuous inflammation may repeatedly destroy the 
epithelial cells [9]. This has to be compensated by 
epithelial increased proliferation, hyperplasia, 
dysplasia which finally can lead to inflammation-
associated colorectal cancer (CRC) [10, 11].  The risk 
is estimated to reach up to 2.4 folds that seen in 
normal population in some studies [12].  
Angiogenesis was proved to play important 
role in carcinogenesis [3]. However, few data are 
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available on pre-malignant conditions [13]. 
Vascular Endothelial Growth Factor (VEGF) is 
a well-known pro-angiogenic factor [14]. It increases 
vascular permeability, stimulates leukocyte adhesion 
to the endothelium, and promotes monocyte 
chemotaxis that promotes tumor neovessel 
angiogenesis.  It has long been proposed as an 
important biomarker for cancer as well as a target for 
anti-angiogenic cancer therapy.  Elevated VEGF 
expression levels are appreciated in most solid 
tumors, including colon carcinoma [15].  
In pre-malignant lesions, VEGF was found to 
be significantly increased in some organs, such as in 
the oral mucosa, skin, and uterine cervix. So, it was 
suggested that tumor angiogenesis is not necessarily 
a characteristic of invasive tumor, but may be an early 
event during tumourigenesis [13]. 
This work aimed at studying the 
immunohistochemical expression of VEGF in colon 
cancer and the related two important precancerous 
lesions; colonic adenomas and ulcerative colitis.  This 
is an attempt to investigate the potential role of VEGF 
in the pathogenesis of colonic neoplasia and 
ulcerative colitis.  
 
Material and Methods 
Paraffin blocks of 55 cases were included; 
twenty cases of colonic cancer of different degrees of 
differentiation, 15 cases of colonic adenoma, and 20 
cases of ulcerative colitis, additional 5 blocks of 
normal colonic mucosa were obtained as a control all 
were collected in the duration of a year from 
2011/2012 from Nasr Institute hospital (specialized 
national Hospitals) and Mahmoud Hospital (Non-
Governmental Organization Hospital). 
Blocks were sectioned at 5 micron thickness 
on positive charged slides, revised for the 
histopathological diagnosis by two independent 
pathologists( A.G & R.SH) and then  stained for VEGF 
immunostains according to the following steps: 
Slides were hydrated in descending grades of 
alcohol followed by distilled water. Endogenous 
peroxidase activity was quenched by 0.3% hydrogen 
peroxide for 5 minutes followed by rinsing in distilled 
water and three times wash in phosphate buffer saline 
(PBS) pH 7.4. The primary mouse antihuman 
monoclonal antibody; Vascular Endothelial Growth 
Factor- VEGF (Clone VG1); DAKO, Denmark; was 
applied and incubated for 30 minutes and then the 
slides were rinsed in successive baths of PBS. DAKO 
Envision detection kit was used. Diaminobenzidine 
tetrachloride (DAB) was used as chromogen.  
Slides were counterstained in Harris 
haematoxylin (Hx), dehydrated, and cleared in xylene 
and coverslipped. Reactive lymph nodes and internal 
control were used as positive control. Slides with 
omitted antibodies were used as negative control. 
Interpretation of IHC 
Cytoplasmic and/or membrane specific 
positive tumor cells were assessed [16]. 
In the literatures, it was observed that the 
interpretation of VEGF in different organs may differ, 
yet it was preferred to interpret according to Zhang et 
al.; being a relatively recent study done on colonic 
tissue as well. According to this study, five fields were 
randomly selected and immunohistochemical staining 
of the cells was assessed according to both the 
proportion of cells stained and the staining intensity. 
The proportion of cells stained was assessed 
using a semiquantitative 4-point scale: 0, <10% 
staining; 1, 10–20% staining; 2, 21–50% staining; and 
3, >50% staining. 
The staining intensity was also graded using a 
4-point scale: 0, no staining; 1, light yellow; 2, brown; 
and 3, dark brown. 
The combined score was calculated by 
multiplying the individual scale of the proportion and 
intensity (range 0–9) and was assessed as follows: 0–
2, negative staining (−); 3–6, positive staining (+); and 
≥6, strong positive staining (++) [3]. 
 
Statistical analysis  
Data were statistically described in terms of 
frequencies (number of cases) and relative 
frequencies (percentages). Chi square (2) test was 
performed to compare the different study variables 
between the study groups. Yates correction and 
Fisher exact tests were used only when the expected 
frequency was found to be less than five. A probability 
value (p value) less than 0.05 was considered 
statistically significant. 
All statistical calculations were done using 
computer programs Microsoft Excel version 7 
(Microsoft Corporation, NY, USA) and SPSS 
(Statistical Package for the Social Science; SPSS 
Inc., Chicago, IL, USA) statistical program.  
 
Results 
Review of the epidemiologic data of the 
studied cases:  - the study included 50 cases; - Cases 
of colonic adenocarcinoma ranged in age from 
34years up to 65years with median of 49 years; - 
Cases of the adenomatous polyps ranged in age from 
31years up to 52years with median of 40 years; - 
cases of ulcerative colitis ranged in age from 27 years 
to 43years with median of 33 years; - among the 
studied cases of adenocarcinoma, the highest 
frequency (72%) occurred in males, while there was 
no significant sex difference in adenomatous polyps 
studied cases (46.7% male: 53.3% female), and in UC 
cases (40% male: 60% females). 
Results of VEGF expression (Table 1, Figure 
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1): - cases of the control group showed absent or 
focal pale staining (combined score 0-2; negative); -
strong cytoplasmic expression for VEGF (combined 
score <6; ++) was observed in 90% of the 
adenocarcinoma cases, rest of the cases (10%) 
showed cytoplasmic positivity (combined score 3-6; 
+). The difference between VEGF expressions in 
carcinomas compared to the control cases was highly 
significant (p=0.001). 
The difference in VEGF immunohistochemical 
expression between adenocarcinoma cases of 
moderate differentiation compared to those of poor 
differentiation was insignificant (p= 0.321). 
All cases of adenomas showed positive 
cytoplasmic reaction for VEGF, The difference in 
VEGF immunohistochemical expression between the 
adenoma cases and the control was significant 
(p=0.002). 
Table1: Immunohistochemical expression of VEGF in the 
different diagnostic groups and their comparison to control 
group.  
 
VEGF 
SCORE 
Studied cases   
Carcinoma -
diffferentiation 
Adenoma - dysplasia     
Ulcerative 
colitis 
Control 
 
Mod. 
N (%) 
Poor 
N (%) 
Mild 
N (%) 
Mod.& 
marked 
N (%) 
N (%) N (%) 
0-2 (-) 0 (0) 0 (0) 0 (0) 0 (0) 4 (26.7) 5 (100) 
3-6 (+) 2 (10) 0 (0) 4 (26.7) 0 (0) 10 (66.7) 0 (0) 
>6 (++) 
12 
(60) 
6 (30) 0 (0) 11 (73.3) 1 (6.7) 0 (0) 
Total  
14 
(70) 
6 (30) 4 (26.7) 11 (73.3) 15 (100) 5 (100) 
P value 
when 
compared 
with the 
control 
p=0.001 P=0.002 P=0.002 p= 0.022 - 
 
Strong positivity (score < 6, ++) was seen in 
73.3% (cases of moderate to marked dysplasia), while 
(combined score 3-6; +) was seen in 26.7% of the 
cases (cases of mild dysplasia).  
 
  
 
 
Figure1: (a) A case of colonic adenocarcinoma showed strong diffuse VEGF cytoplasmic immunostain(X200) (b) A case of colonic adenoma 
with moderate dysplasia showed diffuse strong cytoplasmic immunostain for VEGF(X400), (c) A case of ulcerative colitis showed strong 
cytoplasmic VEGF immunostain in some cells (X200), (d) A normal control showed almost negative VEGF immunostain (X200). 
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The low positivity score was significantly seen 
in mild dysplasia (p= 0.001). The difference in VEGF 
immunohistochemical expression between adenomas 
of marked dysplasia and carcinomas was insignificant 
(p= 0.072), while the difference between adenomas 
with mild dysplasia and cases of adenocarcinomas 
was significant (p= 0.003).  In UC; 26.7% of the cases 
showed negative reaction for VEGF in the epithelial 
cells (combined score 0-2;   -), 66.7% showed positive 
reaction (combined score2-6; +), 6.6% showed strong 
positivity (combined score < 6; ++). 
It was noticed that the lamina propria in all 
cases showed strong VEGF expression.  
In comparison with the control cases; the 
diagnosis of ulcerative colitis was significantly 
associated with VEGF positivity (p= 0.022). 
The overall difference between cases of 
adenocarcinoma and cases of ulcerative colitis in 
VEGF positivity was insignificant (p= 0.1); however, 
high positivity score (> 6-9) was significantly 
associated with adenocarcinoma cases (p= 0.04).  
 
Discussion 
Colon cancer is the third most common 
cancer worldwide in both sexes [8] and one of the 
most frequent cancers in Egypt [2]. 
Colonic adenomas and UC are two 
documented precancerous lesions, whose proper 
control is thought to affect cancer colon incidence 
largely [17].   
Angiogenesis plays a significant role in tumor 
genesis and progression and so its targeting jumped 
to be a priority in oncology [18]. 
In the present study we examined the 
immunohistochemical expression of a potent pro-
angiotic factor VEGF in two premalignant colonic 
lesions; the adenomas and ulcerative colitis, 
compared to its expression in colon cancer cases and 
normal colonic mucosal control in Egypt. 
The study included 20 cases of colorectal 
cancer; 15 cases of adenomatous polyps, 15 case of 
ulcerative colitis and 5 control specimens. 
According to our cases (90%) of colonic 
adenocarcinoma cases were strongly positive for 
VEGF, with no significant differences between cases 
of moderate and poor differentiation. 
The positivity of colon cancer cells for VEGF 
is proved in many studies. Islam et al. stated that 
increased expression of vascular endothelial growth 
factor (VEGF) occurs concurrently with increasing 
vascular density of an invasive tumor of colon cancer 
and increased in the context of metastasis, and 
recurrence [19]. 
Chen et al. stated that the level of VEGF 
expression is significantly raised in colorectal cancer 
compared with polyps and normal mucosa [20]. 
As well Cao et al. got similar results and 
recommended that VEGF should be added to the list 
of biomarkers used in clinical practice for CRC [21].   
In the present study adenoma cases showed 
a significant difference in the expression of VEGF; 
between different grades of dysplasia; positivity 
increasing with the increase in the grade of the 
dysplasia.  
Adenomas with moderate and marked 
dysplasia showed strong VEGF expression in 73.3% 
of cases, while all the cases of adenoma with mild 
dysplasia showed mild positivity.  
  Generally a limited number of studies in the 
literature studied the expression of VEGF in colonic 
adenomas. In 2007, Shin et al., studied the 
expression of VEGF and other factors in cases of 
adenomas, early carcinoma and advanced carcinoma 
and they noticed the increase in the VEGF protein 
expression from adenoma to early cancer to 
advanced cancer cases. Similarly, Raica et al. got 
similar findings. Both studies concluded that VEGF is 
implicated in the progression from adenoma to 
carcinoma and they proposed that estimation of VEGF 
can be helpful in follow up of adenoma cases to detect 
early carcinogenesis and further progression of colon 
cancer [13]. However, both studies didn't correlate the 
expression with the degree of dysplasia in adenomas. 
Cases of UC in the current study showed 
variable results for VEGF reactivity of the epithelial 
mucosal cells; 26.7% of the cases showed negative 
reaction for VEGF (score 0-2,-), 66.7% showed 
positive reaction (score3-6, +), 6.6% showed strong 
positivity (score < 6, ++). Strong VEGF expression is 
seen in the lamina propria in all cases.  
In the literatures, variable results are 
demonstrated: Giatromanolaki et al. found that the 
expression of VEGF in UC was weak. Kapsoritakis et 
al., found that its expression in UC was almost similar 
to that in normal control, both   suggested that the 
pathogenesis of UC is not VEGF dependent [22, 23].   
However, more recent studies; Alkim et al., 
noticed that VEGF is increased in IBD patients’ tissue 
and their sera [24]. As well, Griga et al. found 
increased expression of VEGF in epithelium of the 
inflamed mucosa and non-inflamed mucosa of 
patients of active UC, and in the interstitial lamina 
propria due to accumulation of the VEGF producing 
leucocytes [25].  
Similarly, Tsiolakidou et al. & Tolstanova et 
al., noticed increased VEGF expression in the mucosa 
of UC cases compared to the healthy control, and 
proposed a possible role of angiogenesis in the 
pathogenesis of inflammatory bowel diseases mostly 
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by increasing vascular permeability and promoting the 
infiltration of inflammatory cells [26, 27]. This also was 
the base on which Tolstanova et al., built their 
experimental study, in which they highlighted that   
Neutralizing anti-VEGF antibody significantly 
ameliorates experimental UC in rats in part by 
reducing excessive vascular permeability and 
decreasing inflammatory cells infiltration [28].   
A similar conclusion was achieved by Pousa 
et al., who suggested that a better understanding of 
the angiogenic process may facilitate the design of 
more effective therapies for chronic intestinal 
inflammation [29]. 
As a conclusion, the current work proposes 
that the angiogenic factor VEGF may play a role in the 
pathogenesis of colonic neoplasia and ulcerative 
colitis. This may support the introduction of anti-VEGF 
as adjuvant to chemotherapy in colon cancer 
management, and as a follow up parameter in colonic 
adenomas and UC cases.  
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